Skip to main content
13064 search results for:

mTOR-Inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | mTOR-Inhibitors | OriginalPaper

    High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line

    Cancer is one of the top causes of human death worldwide. In recent decades, many molecular studies have made it possible to significantly extend the 5-year survival rates of various cancers worldwide, but complete remission is rare when cancer …

  2. 10-11-2023 | Tuberous Sclerosis | OriginalPaper

    Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors

    Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder that commonly leads to the development of hamartomas in multiple major organ systems [ 1 ]. The pathogenesis is driven by uncontrolled mTOR activation caused by de novo or …

  3. 26-09-2023 | Kidney Transplantation | OriginalPaper

    Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function

    In our study, we examined the efficacy of mTOR (mammalian target of rapamycin) inhibitors, specifically rapamycin (Rap), compared to calcineurin inhibitors (CNIs) in kidney transplantation. By conducting a comprehensive search across reputable …

  4. 31-10-2023 | Tuberous Sclerosis | OriginalPaper

    An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients

    Tuberous sclerosis complex (TSC) is an autosomal dominant multi-system disease caused by pathogenic variants in TSC1 and TSC2 [ 1 ]. The main pathological findings of TSC are benign tumors in several organs, such as subependymal giant cell …

  5. 01-01-2024 | Hepatocellular Carcinoma | OriginalPaper

    Ammonia scavenger and glutamine synthetase inhibitors cocktail in targeting mTOR/β-catenin and MMP-14 for nitrogen homeostasis and liver cancer

    The glutamine synthetase (GS) facilitates cancer cell growth by catalyzing de novo glutamine synthesis. This enzyme removes ammonia waste from the liver following the urea cycle. Since cancer development is associated with dysregulated urea …

  6. 01-01-2023 | COVID-19 | News

    mTOR-protein-inhibitors/mycophenolate-mofetil/tacrolimus

    COVID-19 infection: 35 case reports
  7. 01-12-2022 | Tuberous Sclerosis

    Perfect match: mTOR inhibitors and tuberous sclerosis complex

    Tuberous sclerosis complex (TSC) is an autosomal dominant syndrome that presents with diverse and complex clinical features and involves multiple human systems. TSC-related neurological abnormalities and organ dysfunction greatly affect the …

  8. Open Access 21-04-2023 | Tuberous Sclerosis | OriginalPaper

    Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age

    Mechanistic target of rapamycin (mTOR) pathway plays a specific role in epileptogenesis in several neurological disorders, belonging to the group of “mTORopathies”, including focal cortical dysplasia, tuberous sclerosis complex (TSC), and …

  9. Open Access 01-12-2022 | mTOR-Inhibitors | ReviewPaper

    Recent advances and limitations of mTOR inhibitors in the treatment of cancer

    The PI3K-Akt-mechanistic (formerly mammalian) target of the rapamycin (mTOR) signaling pathway is important in a variety of biological activities, including cellular proliferation, survival, metabolism, autophagy, and immunity. Abnormal …

  10. Open Access 01-12-2022 | Checkpoint Inhibitors | OriginalPaper

    mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers

    Immune escape of cancer cells driven by immune checkpoints, including PD-1 and CTLA4, yielded hot-spots to be targeted in the recent years [ 1 , 2 ]. The treatment of immune checkpoint inhibitors (ICI) prolonged survival for cancer patients [ 3 , 4 …] and had been adopted in neoadjuvant therapy [

  11. Open Access 01-12-2021 | Astrocytoma | OriginalPaper

    Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility

    Subependymal giant cell astrocytoma (SEGA) is often seen in patients with tuberous sclerosis complex (TSC), with a reported frequency of 1–27.4 % [ 1 – 7 ]. Management of SEGA used to involve resection in open cranial surgery [ 8 , 9 ], because …

  12. 01-07-2020 | Breast Cancer | OriginalPaper

    The Use of Geroprotective Agents (mTOR Inhibitors) in the Treatment of Cancer Patients

  13. Open Access 01-12-2019 | Gastric Cancer | OriginalPaper

    A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

    Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide with nearly one million new cases every year [ 1 ]. GCs are classified into intestinal and diffuse types [ 2 ]. Intestinal-type GCs …

  14. Open Access 01-06-2019 | Adrenocortical Carcinoma | OriginalPaper

    IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer

    Malignant tumors of the adrenal cortex, defined as adrenocortical carcinoma (ACC), are rare but aggressive cancers for which new treatment options are required [ 1 – 4 ]. Although most ACCs are sporadic, ACCs rarely develop in the context of …

  15. 01-06-2020 | Kidney Transplantation

    Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice

    Kidney transplant recipients may benefit from the use of mTOR inhibitors (mTORi) thanks to their anti-neoplastic and anti-viral effects that reduce the incidence of post-transplant neoplasia and CMV reactivation [ 1 – 4 ]. However, in some clinical …

  16. Open Access 01-12-2019 | Tuberous Sclerosis | ReviewPaper

    Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis

    Tuberous sclerosis complex (TSC) is an orphan disease that affects many organ systems to varying degrees and is typically characterized by benign tumors of the skin (facial angiofibroma), brain (subependymal giant cell astrocytoma), kidneys …

  17. 01-07-2019 | Insulins | ReviewPaper

    Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation

    Inhibitors of mechanistic target of rapamycin (mTOR inhibitors) are used as antiproliferative immunosuppressive drugs and have many clinical applications in various drug combinations. Experience in transplantation studies has been gained regarding …

  18. Open Access 01-12-2012 | Letter

    mTOR inhibitors: A novel class of anti-cancer agents

  19. Open Access 01-12-2023 | Breast Cancer | OriginalPaper

    CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

    In 2020, an estimated 2.3 million cases of breast cancer were newly diagnosed worldwide, accounting for approximately 25% of female malignant tumors and overtaking lung cancer as the most common malignancy [ 1 ]. Among these breast cancer cases …

  20. 01-04-2010 | ReviewPaper

    The potential role of mTOR inhibitors in the treatment of endocrine tumors

    Mammalian target of rapamycin (mTOR), a main protein kinase in the phosphoinositide 3-kinase/Akt/p70S6K signaling pathway, is an important intracellular mediator involved in multiple cellular functions including proliferation, differentiation …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.